Qiming Venture Partners and Duane Kuang Win Shanghai Securities News 2025 Eagle Award for Finance

Recently, the "2025 Shanghai Securities News Multi-Tier Capital Market High-Quality Development Conference & Shanghai Securities Eagle · Jinrongzi, Jinyangguang, and Chengxintuo Awards Ceremony," hosted by Shanghai Securities News · China Securities Network under Xinhua News Agency, was held in Nantong, Jiangsu. At the conference, Shanghai Securities News announced the results of the 2025 "Shanghai Securities Eagle · Jinrongzi" equity investment awards. Qiming Venture Partners won the Shanghai Securities Eagle · Outstanding Investment Institution Award, and Duane Kuang, Founding Managing Partner of Qiming Venture Partners, won the Shanghai Securities Eagle · Outstanding Investor Award.

Qiming Venture Partners

Wins

Outstanding Investment Institution Award

Duane Kuang, Founding Managing Partner of Qiming Venture Partners

Wins

Outstanding Investor Award

Selection Criteria

The "Shanghai Securities Eagle · Jinrongzi Awards" are determined through three components: quantitative assessment (40% weighting), qualitative evaluation (40% weighting), and online voting (20% weighting). Based on its evaluation guidelines, Shanghai Securities News conducts comprehensive quantitative and qualitative scoring of participating institutions' fundraising, investment, management, and exit data, adhering to principles of openness, fairness, and impartiality to select the 2025 "Shanghai Securities Eagle · Jinrongzi Awards."

Source | Shanghai Securities News

Past Highlights

Qiming ESG | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Relief Fund to Support Post-Disaster Reconstruction | Bilingual Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Hong Kong Has Become an Important Financing Channel for Hard Tech Companies Going Global Qiming Honors | Qiming Venture Partners Wins Three Awards Including China Venture Capital Research Institute · 2025 China Venture Capital Industry Annual Golden Investment Award

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.

Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Arbutus Biopharma, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.